Roche acquires Spark Therapeutics for $4.3 billion Acquisitions, Analysts, Blindness, Blockbusters, Business, Cancer, Cells, Choroideremia, Gene Therapy, Hemophilia A, Hemophilia B, Huntington's Disease, Immune System, Immuno-oncology, Inherited Diseases, Leber’s Congenital Amaurosis, M&A, Pompe disease, Rare Diseases, Rare Genetic Diseases, Rare Inherited Disorders, Shares, Spinal Muscular Atrophy (SMA), Steroids Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said. Read more February 25, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-02-25 01:23:172019-02-25 13:26:18Roche acquires Spark Therapeutics for $4.3 billion
